Drugs / RBV
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT00983060 Background | Sep 2009 → Apr 2011 | — | Novartis Pharmaceuticals | Completed | No outcome recorded |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | RBV | “BID in various doses (between 100 mg - 600 mg bid) + SOC (PEG IFN and RBV)” NCT00983060 ↗ |